Blau Farmacêutica S.A. (BLAU3.SA)
BRL 13.33
(3.25%)
BRL 13.33
(3.25%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 603.73 Million BRL | 95.99% |
| 2022 | 308.04 Million BRL | -17.28% |
| 2021 | 372.4 Million BRL | -45.99% |
| 2020 | 689.52 Million BRL | 147.21% |
| 2019 | 278.92 Million BRL | 23.89% |
| 2018 | 225.13 Million BRL | 116.65% |
| 2017 | 103.91 Million BRL | -26.77% |
| 2016 | 141.9 Million BRL | -6.83% |
| 2015 | 152.31 Million BRL | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 599.38 Million BRL | -0.72% |
| 2024 Q2 | 554.32 Million BRL | -7.52% |
| 2023 Q3 | 598.41 Million BRL | 149.41% |
| 2023 FY | 603.73 Million BRL | 95.99% |
| 2023 Q1 | 313.64 Million BRL | 1.82% |
| 2023 Q4 | 603.73 Million BRL | 0.89% |
| 2023 Q2 | 239.93 Million BRL | -23.5% |
| 2022 Q2 | 314.46 Million BRL | -4.09% |
| 2022 FY | 311.71 Million BRL | -17.28% |
| 2022 Q4 | 308.04 Million BRL | -1.82% |
| 2022 Q3 | 313.74 Million BRL | -0.23% |
| 2022 Q1 | 327.86 Million BRL | -11.96% |
| 2021 Q4 | 372.4 Million BRL | -25.72% |
| 2021 Q2 | 490.76 Million BRL | -37.97% |
| 2021 Q1 | 791.19 Million BRL | 14.74% |
| 2021 FY | 374.51 Million BRL | -45.99% |
| 2021 Q3 | 501.38 Million BRL | 2.16% |
| 2020 FY | 690.01 Million BRL | 147.21% |
| 2020 Q4 | 689.52 Million BRL | 10.17% |
| 2020 Q3 | 625.86 Million BRL | 23.36% |
| 2020 Q2 | 507.34 Million BRL | 83.14% |
| 2020 Q1 | 277.03 Million BRL | -0.68% |
| 2019 Q1 | 231.64 Million BRL | 2.89% |
| 2019 Q2 | 224.94 Million BRL | -2.89% |
| 2019 Q4 | 278.92 Million BRL | 24.57% |
| 2019 Q3 | 223.89 Million BRL | -0.46% |
| 2019 FY | 278.92 Million BRL | 23.89% |
| 2018 Q4 | 225.13 Million BRL | 0.0% |
| 2018 FY | 225.13 Million BRL | 116.65% |
| 2017 FY | 103.91 Million BRL | -26.77% |
| 2016 FY | 141.9 Million BRL | -6.83% |
| 2015 FY | 152.31 Million BRL | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Hypera S.A. | 10.11 Billion BRL | 94.029% |